Preplanned continuation of the Denosumab and Teriparatide Administration ( DATA ) randomized controlled trial in which postmenopausal osteoporotic women received teriparatide ( 20 g daily ) , denosumab ( 60 mg every 6 months ) , or both medications for 24 months .